Realistic net-prices and peak-patient-shares are key requirements for providing early commercial direction for assets whose clinical profile might not yet been finalised. Early to mid-stage commercial decision-making benefits from specialised tools that have been specifically developed for this purpose. During the past year groupH developed an evidence-based Peak-Patient-Share tool (a.k.a. the Devil’s Advocate Tool) that […]